Profile and variables related to antipsychotic consumption according to dementia subtypes

Calvó-Perxas, Laia; Eugenio, Rosa María de; Marquez-Daniel, Fabian; Martínez, Raül; Serena, Joaquı́n; Turbau, Josefa; Vilalta-Franch, Joan; Viñas, Marta; Turró‐Garriga, Oriol; Roig, Anna Maria; López-Pousa, Secundino; Garré-Olmo, Josep

doi:10.1017/s1041610212000026

Cited by 20 publications

(12 citation statements)

References 29 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antipsychotic drugs were identified by their Anatomical and Therapeutic Chemical (ATC) code N05A. N05AE04, N05AH02, N05AH03, N05AH04, N05AX08, and N05AX12 were coded as second‐generation antipsychotics, and all other antipsychotics were coded as first‐generation antipsychotics . All persons who were dispensed one or more antipsychotic drugs during the study period were considered as antipsychotic drug users.…”

Section: Methodsmentioning

confidence: 99%

Educational disparities in antipsychotic drug use among older people with and without dementia in Sweden

Wastesson

Weitoft

Johnell

2014

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Educational disparities in antipsychotic drug use among older people with and without dementia in Sweden

Wastesson

Weitoft

Johnell

2014

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

“…Regarding antipsychotics, serious side effects and increased mortality risk have been repeatedly documented [11,39,40], but they are broadly used in patients with dementia [15,37]. Yet, according to our results, early diagnosed patients (<12 months) were less frequently prescribed an antipsychotic (18.4%) compared to those diagnosed later (30.8% in ≥36 months).…”

Section: Discussionmentioning

confidence: 48%

“…Today, AD patients are broadly treated with antidementia drugs to improve cognitive and functional domains [13], and with neuroleptics, antidepressants, anxiolytics and other drugs to deal with behavioral and psychological symptoms [14]. So far, some studies have analyzed the drug prescription patterns in patients with AD, and most of them have focused on nursing homes, community-dwelling patients, or in specific drugs or families of drugs [15,16,17,18,19]. Besides, some authors describe medication patterns according to the severity of the dementia [20], but to our knowledge, there are no reports examining whether differences exist between the central nervous system (CNS) drug consumption pattern of individuals who are diagnosed as having AD, depending on the time elapsed between the first symptoms and the diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Central Nervous System Drug Consumption Depending on the Time between Symptom Onset and the Diagnosis of Alzheimer’s Disease: An Analysis by the Registry of Dementias of Girona

Calvó-Perxas

López-Pousa²,

Vilalta-Franch³

et al. 2012

Dement Geriatr Cogn Disord

Self Cite

View full text Add to dashboard Cite

Aims: To describe central nervous system (CNS) drug consumption patterns depending on the time to diagnosis of Alzheimer’s disease (AD), and to check whether the cases diagnosed later are associated with greater severity and consuming more CNS drugs. Methods: Cross-sectional study using 952 cases of the Registry of Dementias of Girona. A binary logistic regression was used to detect variables associated with the use of CNS drugs depending on the time to diagnosis. Results: CNS drugs were consumed by 95.8% of the AD patients. Only antipsychotics presented a statistically significant increase in the frequency of prescription to patients with longer time elapsed from symptom onset to AD diagnosis. Conclusion: Longer time elapsed from the onset of symptoms to the diagnosis resulted in increased probability of antipsychotic consumption.

show abstract

“…In late-onset dementia, dementia severity has been found to be positively associated with psychotropic drug use, but Koopmans et al did not find this relationship in young-onset dementia (Calvo-Perxas et al, 2012;Koopmans et al, 2014). Additionally, in late-onset dementia, no differences in the use of antipsychotics have been found between people with Alzheimer's disease (AD), vascular dementia (VaD) and frontotemporal dementia (FTD) (Calvo-Perxas et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Psychotropic drug use in community-dwelling people with young-onset dementia: two-year course and determinants

Gerritsen¹,

Bakker²,

Bruls³

et al. 2019

Aging & Mental Health

View full text Add to dashboard Cite

Objectives: The aim of this study was to describe the course of psychotropic drug use in people with young-onset dementia and to explore possible associations with age, sex, dementia severity, dementia subtype and neuropsychiatric symptoms. Methods: Psychotropic drug use was studied in 198 community-dwelling persons participating in the Needs in Young-onset Dementia study. Data about psychotropic drug use were retrieved at baseline, as well as at 6, 12, 18 and 24 months and was classified into five groups (antiepileptics, antipsychotics, anxiolytics, hypnotics/sedatives and antidepressants) and quantified as 'present' or 'absent'. Generalized Estimating Equation modeling and chi-square tests were used to study associations between the determinants and psychotropic drug use. Results: There was a statistically significant increase in the prevalence of psychotropic drug use from 52.3% to 62.6% during the course of the study. Almost three-quarters (72.4%) of the participants were treated with any psychotropic drug during the study, and more than one-third (37.4%) received psychotropic drugs continuously. Antipsychotics were used continuously in more than 10% of the participants and antidepressants in more than 25%. Increasing age was positively associated (p ¼ .018) with psychotropic drug use at baseline, while apathy symptoms were negatively associated (p ¼ .018). Conclusions: Despite the recommendations of various guidelines, the prolonged use of psychotropic drugs in community-dwelling people with young-onset dementia is high. Therefore, more attention is needed to timely evaluate psychotropic drug use and the introduction of self-management programs for caregivers should be encouraged to support caregivers in dealing with the neuropsychiatric symptoms caused by the dementia.

show abstract

Profile and variables related to antipsychotic consumption according to dementia subtypes

Abstract: Despite their disputed benefit-risk ratios, APs are extensively used, off-label, to treat BPSD, and AAPs are more commonly prescribed than TAPs. AP consumption was frequent in DLB, and was related to dementia severity indicators.

Cited by 20 publications

References 29 publications

Educational disparities in antipsychotic drug use among older people with and without dementia in Sweden

Educational disparities in antipsychotic drug use among older people with and without dementia in Sweden

Central Nervous System Drug Consumption Depending on the Time between Symptom Onset and the Diagnosis of Alzheimer’s Disease: An Analysis by the Registry of Dementias of Girona

Psychotropic drug use in community-dwelling people with young-onset dementia: two-year course and determinants

Contact Info

Product

Resources

About